Luye Pharma Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Luye Pharma Group şirketinin kazançları yıllık ortalama -27.5% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 5.7% oranında artan oldu. Gelirler yıllık ortalama 0.03% oranında azalan oldu. Luye Pharma Group şirketinin öz sermaye getirisi 5.9% olup, net marjı 12.2% dir.

Anahtar bilgiler

-27.5%

Kazanç büyüme oranı

-31.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	5.6%
Gelir büyüme oranı	-0.03%
Özkaynak getirisi	5.9%
Net Marj	12.2%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Sep 25

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Aug 29

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Jun 19

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Aug 17

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

May 10

We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Sep 20

Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook

Apr 06

Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares

Mar 17

Gelir ve Gider Dağılımı

Luye Pharma Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:2186 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	6,314	770	2,428
31 Mar 24	6,228	652	2,564
31 Dec 23	6,143	533	2,700
30 Sep 23	6,089	495	2,705
30 Jun 23	6,035	458	2,711
31 Mar 23	6,008	531	2,557
31 Dec 22	5,982	605	2,403
30 Sep 22	5,541	190	2,365
30 Jun 22	5,099	-224	2,327
31 Mar 22	5,150	-179	2,301
31 Dec 21	5,200	-134	2,276
30 Sep 21	5,365	210	2,196
30 Jun 21	5,529	554	2,116
31 Mar 21	5,534	630	2,151
31 Dec 20	5,540	707	2,185
30 Sep 20	5,864	955	2,302
30 Jun 20	6,189	1,204	2,419
31 Mar 20	6,273	1,300	2,491
31 Dec 19	6,358	1,396	2,564
30 Sep 19	6,229	1,434	2,506
30 Jun 19	6,101	1,472	2,448
31 Mar 19	5,637	1,388	2,287
31 Dec 18	5,173	1,303	2,127
30 Sep 18	4,671	1,231	1,957
30 Jun 18	4,168	1,159	1,787
31 Mar 18	3,991	1,070	1,753
31 Dec 17	3,815	981	1,718
30 Sep 17	3,547	917	1,629
30 Jun 17	3,280	852	1,539
31 Mar 17	3,099	872	1,464
31 Dec 16	2,918	892	1,389
30 Sep 16	2,784	843	1,310
30 Jun 16	2,649	794	1,232
31 Mar 16	2,606	774	1,190
31 Dec 15	2,563	755	1,149
30 Sep 15	2,481	732	1,037
30 Jun 15	2,400	710	924
31 Mar 15	2,472	658	1,046
31 Dec 14	2,544	606	1,168
30 Sep 14	2,705	534	1,415
30 Jun 14	2,866	462	1,661
31 Mar 14	2,690	386	1,593
31 Dec 13	2,515	310	1,525

Kaliteli Kazançlar: 2186 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 2186 'nin mevcut net kar marjları (12.2%) geçen yılın (7.6%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 2186 şirketinin kazançları son 5 yılda yılda 27.5% oranında azaldı.

Büyüme Hızlandırma: 2186 'un son bir yıldaki kazanç büyümesi ( 68.3% ) 5 yıllık ortalamasını (yıllık -27.5% ) aşıyor.

Kazançlar vs. Sektör: 2186 geçen yılki kazanç büyümesi ( 68.3% ) Pharmaceuticals sektörünün 6.4% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 2186 'nin Özsermaye Getirisi ( 5.9% ) düşük olarak değerlendiriliyor.

Luye Pharma Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Consensus EPS estimates increase by 24%, revenue downgraded

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.

Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Now 20% overvalued

Now 23% overvalued

Full year 2023 earnings: EPS misses analyst expectations

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao

Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610

Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States

Now 20% undervalued after recent price drop

Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Investor sentiment deteriorates as stock falls 17%

Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong

Luye Pharma Group Ltd. Announces Board Changes

A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 16%

Is Luye Pharma Group (HKG:2186) A Risky Investment?

Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin

Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China

Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy

Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan

Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

Consensus EPS estimates fall by 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)

FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder

Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)

Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014

Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate

Less than half of directors are independent

Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA

Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding

First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021)

Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China

Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan

Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in China

Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual Meeting

Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual Meeting

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in China

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for Injection